Targeted Approaches to T-Cell Lymphoma.
immunotherapy
monoclonal antibodies
novel agents
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
12
05
2021
revised:
24
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
Identifiants
pubmed: 34072040
pii: jpm11060481
doi: 10.3390/jpm11060481
pmc: PMC8229513
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2011 Feb 24;364(8):775-6
pubmed: 21345110
Blood. 2008 Jun 15;111(12):5496-504
pubmed: 18385450
Leukemia. 2020 Dec;34(12):3413-3419
pubmed: 32753688
Blood. 2017 Apr 27;129(17):2437-2442
pubmed: 28188133
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Invest Dermatol. 2002 Dec;119(6):1405-10
pubmed: 12485447
Inflamm Res. 2017 Jul;66(7):571-578
pubmed: 28283679
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Cancer Res. 2014 Nov 1;74(21):6060-70
pubmed: 25361998
Blood. 2018 Jan 25;131(4):397-407
pubmed: 29141948
Ann Oncol. 2021 Apr;32(4):552-559
pubmed: 33352201
Blood. 2021 Apr 22;137(16):2161-2170
pubmed: 33171487
Ann Hematol. 2014 Mar;93(3):459-62
pubmed: 24441915
Blood. 2010 Nov 4;116(18):3418-25
pubmed: 20660290
Blood. 2018 Feb 22;131(8):888-898
pubmed: 29233821
Invest New Drugs. 2010 Dec;28 Suppl 1:S3-20
pubmed: 21161327
Eur J Cancer. 2013 Sep;49(13):2869-76
pubmed: 23731832
Cancers (Basel). 2020 Aug 15;12(8):
pubmed: 32824175
Front Oncol. 2019 Jun 04;9:443
pubmed: 31214498
J Clin Oncol. 2014 Apr 10;32(11):1157-63
pubmed: 24616310
J Clin Oncol. 2012 Mar 10;30(8):837-42
pubmed: 22312108
Blood. 2003 Jun 1;101(11):4267-72
pubmed: 12543862
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Br J Dermatol. 2014 Mar;170(3):720-4
pubmed: 24438061
Cancer. 2019 May 1;125(9):1507-1517
pubmed: 30694529
Cancers (Basel). 2020 Oct 26;12(11):
pubmed: 33114606
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3625-34
pubmed: 14506150
Br J Haematol. 2018 Nov;183(3):497-501
pubmed: 29076126
Immunity. 2010 Aug 27;33(2):153-65
pubmed: 20732639
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
Ann Oncol. 2017 Sep 01;28(9):2169-2178
pubmed: 28633365
Blood. 2014 May 15;123(20):3095-100
pubmed: 24652992
Med J Aust. 2020 Nov;213(9):404-406.e1
pubmed: 32951222
Drugs. 2017 Apr;77(5):505-520
pubmed: 28205024
J Immunol. 2014 Jul 15;193(2):688-99
pubmed: 24943215
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
J Clin Oncol. 2012 Feb 20;30(6):631-6
pubmed: 22271479
Lancet Oncol. 2019 Aug;20(8):1160-1170
pubmed: 31253572
Nat Rev Immunol. 2005 Apr;5(4):284-95
pubmed: 15803148
Haematologica. 2016 Oct;101(10):e407-e410
pubmed: 27418646
Haematologica. 2007 Jun;92(6):784-94
pubmed: 17550851
Blood. 2014 Nov 20;124(22):3330-2
pubmed: 25414436
J Clin Oncol. 2015 Nov 10;33(32):3750-8
pubmed: 26195720
Am J Pathol. 2009 Feb;174(2):661-70
pubmed: 19147828
Cell Mol Immunol. 2013 Nov;10(6):456-8
pubmed: 24037183
J Clin Oncol. 2010 Apr 10;28(11):1870-7
pubmed: 20212249
Eur J Haematol. 2003 Oct;71(4):250-6
pubmed: 12950233
Cancer Res. 1996 Jun 1;56(11):2590-5
pubmed: 8653702
Clin Cancer Res. 2011 Oct 15;17(20):6428-36
pubmed: 22003070
Leukemia. 2021 Jan;35(1):143-155
pubmed: 32382083
Ther Adv Med Oncol. 2020 May 27;12:1758835920923829
pubmed: 32550864
Blood Adv. 2020 Oct 13;4(19):4640-4647
pubmed: 33002132
Blood. 2015 Jun 25;125(26):4024-31
pubmed: 25887777
Blood. 2018 Nov 22;132(21):2305-2309
pubmed: 30279227
J Immunother Cancer. 2018 Dec 27;6(1):158
pubmed: 30587236
Blood. 2007 Jan 1;109(1):31-9
pubmed: 16960145
J Clin Oncol. 2010 Oct 10;28(29):4485-91
pubmed: 20697094
J Hematol Oncol. 2018 Jan 31;11(1):15
pubmed: 29386072
Am J Hematol. 2020 Dec;95(12):E319-E321
pubmed: 32808682
Sci Transl Med. 2012 Jan 18;4(117):117ra7
pubmed: 22261031
Eur J Cancer. 2021 May;148:411-421
pubmed: 33794441
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Ann Oncol. 2017 Sep 01;28(9):2199-2205
pubmed: 28911074
Clin Infect Dis. 2006 Jul 1;43(1):16-24
pubmed: 16758413
J Hematol Oncol. 2019 Dec 29;12(1):141
pubmed: 31884955
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
J Clin Oncol. 2015 Nov 10;33(32):3759-65
pubmed: 26261247
Blood. 2002 Mar 1;99(5):1505-11
pubmed: 11861261
Cancer Sci. 2020 Dec;111(12):4540-4547
pubmed: 33010107
Cell Signal. 2011 Apr;23(4):603-8
pubmed: 20940048
Blood. 2020 Nov 19;136(21):2401-2409
pubmed: 32730586
J Natl Cancer Inst. 2014 Feb;106(2):djt378
pubmed: 24491302
Blood. 2017 Dec 21;130(25):2691-2692
pubmed: 29269528
Arch Dermatol Res. 2021 Jan;313(1):25-31
pubmed: 32270320
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35750419
Haematologica. 2019 May;104(5):993-1003
pubmed: 30573506
J Clin Oncol. 2009 Nov 10;27(32):5410-7
pubmed: 19826128
Blood Adv. 2018 Apr 24;2(8):871-876
pubmed: 29669753
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3
pubmed: 31029646
Leukemia. 2010 Jan;24(1):229-32
pubmed: 19776763
Blood. 2016 Jun 23;127(25):3142-53
pubmed: 27151889
Science. 1994 Mar 4;263(5151):1281-4
pubmed: 8122112
Ann Oncol. 2011 Jul;22(7):1595-1600
pubmed: 21212158
Blood Cancer J. 2017 Sep 8;7(9):e603
pubmed: 28885612
Leuk Lymphoma. 2010 Mar;51(3):447-55
pubmed: 20141439